专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US06673767B1 Gel composition and methods 失效
标题翻译：凝胶组成和方法
公开(公告)号：US06673767B1
公开(公告)日：2004-01-06
申请号：US09532337
申请日：2000-03-21
申请人： Kevin J. Brodbeck , Ann T. Gaynor-Duarte , Theodore Tao-Ian Shen
发明人： Kevin J. Brodbeck , Ann T. Gaynor-Duarte , Theodore Tao-Ian Shen
IPC分类号： A61K3827
CPC分类号： A61K9/0024 , A61K9/0019 , A61K38/21 , A61K38/212 , A61K38/27 , A61K47/02 , A61K47/10 , A61K47/14 , A61K47/34
摘要： Methods and compositions for systemically or locally administering by implantation a beneficial agent to a subject are described, and include, for example, compositions having burst indices of 8 or less for systemic applications and systems releasing 10% or less of the total dose of beneficial agent in the first 24 hours after implantation for local applications. The compositions include a biocompatible polymer, a biocompatible solvent having low water miscibility that forms a viscous gel with the polymer and limits water uptake by the implant, and a beneficial agent.
摘要翻译：描述了通过将有益剂植入受试者来全身或局部施用的方法和组合物，并且包括例如用于系统应用的爆发指数为8或更小的组合物，释放有益剂总剂量的10％或更少的体系在植入后的前24小时内进行本地应用。组合物包括生物相容性聚合物，具有低水混溶性的生物相容性溶剂，其与聚合物形成粘性凝胶并限制植入物吸收水分，以及有益剂。

2. 发明授权

US06471977B1 Aqueous prolonged release formulation 失效
标题翻译：水性延长释放制剂
公开(公告)号：US06471977B1
公开(公告)日：2002-10-29
申请号：US08696985
申请日：1996-08-02
申请人： Michael John Hageman , Margaret Luise Possert
发明人： Michael John Hageman , Margaret Luise Possert
IPC分类号： A61K3827
CPC分类号： A61K38/27
摘要： Prolonged parenteral release into the circulatory system of a cow of a bioactive bovine somatotropin at desirably effective levels can be achieved using novel compositions in which the bovine somatotropin is present it an aqueous liquid at a dose of at least about 150 mg and at a concentration of at least about 50 mg/ml. The aqueous bovine somatotropin formulation provides for the sustained release of bovine somatotropin into the circulatory system of the animal for greater than three (3) days.
摘要翻译：可以使用新的组合物来实现生物活性的牛生长激素的牛的循环系统的长期肠胃外释放，其中牛生长激素以至少约150mg的剂量存在水性液体并且浓度为至少约50mg / ml。牛生长激素水溶液配方提供牛生长激素持续释放到动物的循环系统中大于三（3）天。

3. 发明授权

US06770624B2 Treatment of heart failure with growth hormone 失效
标题翻译：用生长激素治疗心力衰竭
公开(公告)号：US06770624B2
公开(公告)日：2004-08-03
申请号：US09938853
申请日：2001-08-23
申请人： John Ross, Jr. , Kenneth R. Chien
发明人： John Ross, Jr. , Kenneth R. Chien
IPC分类号： A61K3827
CPC分类号： A61K38/27
摘要： Heart failure following myocardial infarction is treated by administration of an angiotensin II inhibitor for 8-12 weeks, followed by administration of a growth hormone for 1-3 weeks.
摘要翻译：通过施用血管紧张素II抑制剂治疗心肌梗死后的心力衰竭8-12周，然后施用生长激素1-3周。

4. 发明授权

US06559289B1 Use of growth hormone or analogues thereof for the treatment of mammals with familial hypercholesterolemia 失效
标题翻译：使用生长激素或其类似物用于治疗具有家族性高胆固醇血症的哺乳动物
公开(公告)号：US06559289B1
公开(公告)日：2003-05-06
申请号：US09830077
申请日：2001-04-23
申请人： Mats Rudling , Bo Angelin
发明人： Mats Rudling , Bo Angelin
IPC分类号： A61K3827
CPC分类号： A61K38/27 , Y10S930/12
摘要： The invention relates to the use of compounds selected from GH, analogues thereof, and GH-releasing compounds, optionally in combination with lipid-lowering agents or therapy, for the preparation of a drug for treatment of mammals with familial hypercholesterolemia of homozygous form.
摘要翻译：本发明涉及选自GH，其类似物和释放GH的化合物，任选地与降脂剂或治疗组合的化合物在制备用于治疗家族性纯合子高胆固醇血症的哺乳动物的药物中的用途。

5. 发明授权

US06468961B1 Gel composition and methods 失效
标题翻译：凝胶组成和方法
公开(公告)号：US06468961B1
公开(公告)日：2002-10-22
申请号：US09615568
申请日：2000-07-13
申请人： Kevin J. Brodbeck , Ann T. Gaynor-Duarte , Theodore Tao-Ian Shen
发明人： Kevin J. Brodbeck , Ann T. Gaynor-Duarte , Theodore Tao-Ian Shen
IPC分类号： A61K3827
CPC分类号： A61K9/0024 , A61K9/0019 , A61K38/21 , A61K38/212 , A61K38/27 , A61K47/02 , A61K47/10 , A61K47/14 , A61K47/34
摘要： Methods and compositions for systemically or locally administering by implantation a beneficial agent to a subject are described, and include, for example, compositions having burst indices of 8 or less for systemic applications and systems releasing 10% or less of the total dose of beneficial agent in the first 24 hours after implantation for local applications. The compositions include a biocompatible polymer, a biocompatible solvent having low water miscibility that forms a viscous gel with the polymer and limits water uptake by the implant, and a beneficial agent.
摘要翻译：描述了通过将有益剂植入受试者来全身或局部施用的方法和组合物，并且包括例如用于系统应用的爆发指数为8或更小的组合物，释放有益剂总剂量的10％或更少的体系在植入后的前24小时内进行本地应用。组合物包括生物相容性聚合物，具有低水混溶性的生物相容性溶剂，其与聚合物形成粘性凝胶并限制植入物吸收水分，以及有益剂。

6. 发明授权

US06800740B1 Variants of native growth hormones having non naturally occurring amino acid sequences or covalent modifications 失效
标题翻译：具有非天然存在的氨基酸序列或共价修饰的天然生长激素的变体
公开(公告)号：US06800740B1
公开(公告)日：2004-10-05
申请号：US08479883
申请日：1995-06-07
申请人： Brian C. Cunningham , James A. Wells
发明人： Brian C. Cunningham , James A. Wells
IPC分类号： A61K3827
CPC分类号： C12N15/8509 , A01K2207/15 , A01K2217/00 , A01K2217/05 , A01K2267/03 , A61K38/00 , C07K14/505 , C07K14/535 , C07K14/5412 , C07K14/57554 , C07K14/61 , C07K16/2869 , G01N33/74 , G01N2333/61
摘要： Growth hormones contain two receptor binding sites termed site 1 and site 2 with which they form ternary complexes with their receptors. In this scheme, site 1 on the hormone binds to one molecule of receptor and then site 2 binds to another molecule of receptor, thereby producing a 1:2 complex. Disclosed herein are growth hormone variants consisting of modifications to the native sequence in the region of site 1 or site 2, or alternatively a combination of modifications at both site 1 and site 2.
摘要翻译：生长激素含有两个受体结合位点，称为位点1和位点2，它们与其受体形成三元复合物。在该方案中，激素上的位点1与一个受体分子结合，然后位点2与另一个受体分子结合，从而产生1：2复合物。本文公开了生长激素变体，其包含对位点1或位点2区域中的天然序列的修饰，或者在位点1和位点2处的修饰组合。

7. 再颁专利

USRE37850E1 Recombinant human endothelial cell growth factor 有权
标题翻译：重组人内皮细胞生长因子
公开(公告)号：USRE37850E1
公开(公告)日：2002-09-17
申请号：US09538857
申请日：2000-03-28
申请人： Michael C. Jaye , Wilson Burgess , Thomas Maciag , William N. Drohan
发明人： Michael C. Jaye , Wilson Burgess , Thomas Maciag , William N. Drohan
IPC分类号： A61K3827
CPC分类号： C07K14/501 , A61K38/00 , Y10S930/12
摘要： Endothelial cell growth factor is achieved through the application of recombinant DNA technology to prepare cloning vehicles encoding the ECGF protein and procedures are disclosed for recovering ECGF protein essentially free of other proteins of human origin. The product is useful for, among other purposes, diagnostic applications and as potential in the treatment of damaged blood vessels or other endothelial cell-lined structures.
摘要翻译：内皮细胞生长因子通过应用重组DNA技术来制备编码ECGF蛋白质的克隆载体，公开了用于回收基本上不含人源蛋白质的ECGF蛋白质的方法。该产品除了其它目的之外还可用于诊断应用，并且用于治疗损伤的血管或其它内皮细胞内衬结构的潜力。

8. 发明授权

US06451347B1 Method for purifying human growth hormone 失效
标题翻译：纯化人生长激素的方法
公开(公告)号：US06451347B1
公开(公告)日：2002-09-17
申请号：US09260362
申请日：1999-03-01
申请人： Warren E. Jaworowicz
发明人： Warren E. Jaworowicz
IPC分类号： A61K3827
CPC分类号： C07K14/61 , A61K38/00
摘要： A method of purifying human growth hormone (hGH) from deamidated hGH, oxidized hGH or both. The method comprises the steps of forming a metal cation complexed-hGH composition enriched in native hGH under conditions wherein none or less than all of the deamidated hGH, oxidized hGH or both complex with a metal cation and, isolating the metal cation-complexed hGH composition from the deamidated hGH, oxidized hGH or combination thereof. The method can further comprise the step of releasing purified hGH from the complex. Alternatively, the metal cation-complexed hGH can be encapsulated into a biocompatible polymer for sustained release of hGH. The purification method can be performed one or more times using the hGH released from the metal cation-complexed hGH composition, depending on the purity of the hGH desired.
摘要翻译：从脱酰胺hGH，氧化hGH或两者纯化人生长激素（hGH）的方法。该方法包括以下步骤：在不存在或少于所有脱酰胺hGH，氧化hGH或二者与金属阳离子络合的条件下形成富含天然hGH的金属阳离子复合hGH组合物，并分离金属阳离子络合的hGH组合物从脱酰胺hGH，氧化hGH或其组合。该方法还可以包括从复合物中释放纯化的hGH的步骤。或者，金属阳离子络合的hGH可以包封在生物相容性聚合物中以持续释放hGH。取决于所需的hGH的纯度，可以使用从金属阳离子络合的hGH组合物释放的hGH一次或多次进行纯化方法。

9. 发明授权

US06429296B2 Complex of human growth hormone and zinc and use 失效
标题翻译：人体生长激素和锌的复合物和使用
公开(公告)号：US06429296B2
公开(公告)日：2002-08-06
申请号：US09767144
申请日：2001-01-23
申请人： Yutaka Yamagata , Masafumi Misaki , Susumu Iwasa
发明人： Yutaka Yamagata , Masafumi Misaki , Susumu Iwasa
IPC分类号： A61K3827
CPC分类号： A61K9/1647 , A61K38/27 , C07K14/61 , Y10S530/839
摘要： The present invention provides a complex of human growth hormone and zinc containing human growth hormone and zinc at a molar ratio of about 1:1.6 to about 1:2.4, and a sustained-release preparation which comprises the complex of human growth hormone and zinc and a biodegradable polymer and which has a high entrapment ratio of human growth hormone and exhibits a stable sustained-release suppressing the initial burst.
摘要翻译：本发明提供人体生长激素和含锌人体生长激素和锌的复合物，其摩尔比为约1:1.6至约1:2.4，以及包含人生长激素和锌的复合物的缓释制剂和可生物降解的聚合物，并且其具有高的人生长激素的截留比并表现出稳定的持续释放，抑制了初始爆发。

10. 发明授权

US06399565B1 Therapeutic use of 20-kilodalton human growth hormone 失效
标题翻译：治疗使用20千道尔顿人生长激素
公开(公告)号：US06399565B1
公开(公告)日：2002-06-04
申请号：US08990774
申请日：1997-12-15
申请人： Noriaki Asada , Miwa Ikeda , Masaru Honjo , Kazutoshi Horikomi , Takeshi Kamioka
发明人： Noriaki Asada , Miwa Ikeda , Masaru Honjo , Kazutoshi Horikomi , Takeshi Kamioka
IPC分类号： A61K3827
CPC分类号： C07K14/61 , A61K38/00
摘要： Administration of an administrative amount of an authentic human growth hormone having a molecular weight of 20,000 daltons to human adults can improve body composition, stimulate lipolysis, increase serum insulin-like growth factor I or be used in replacement therapy for human growth hormone-deficient patients.
摘要翻译：向人类成年人行使管理量的具有20,000道尔顿分子量的真实人生长激素可以改善身体组成，刺激脂肪分解，增加血清胰岛素样生长因子I或用于人类生长激素缺乏患者的替代疗法。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式